Affiliations of authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD (LAB, MBC, RTF, JHL); Section on Environment and Radiation, International Agency for Research on Cancer, Lyon, France (VM); Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada (KCJ); Department of Oncology, Lund University, Lund, Sweden (HO); Department of Preventive Medicine, University of Southern California, Los Angeles, CA (JTC, BEH, MCP, GU); Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, UK (RC, AJS); Epidemiology Research Program, American Cancer Society, Atlanta, GA (SMG, MMG); Department of Medicine (JMG), Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics, Gynecology and Reproductive Biology (KBM), and Divisions of Preventive Medicine and Aging (HDS), Brigham and Women's Hospital, Boston, MA; MAVERIC, VA Boston Healthcare System, Boston, MA (JMG); Department of Surgery, Aretaieion University Hospital, Athens, Greece (GG); Center for Research in Epidemiology and Population Health, INSERM Unit 1018, Paris-Sud University, Villejuif, France (PG); AARP Research, AARP, Washington, DC (AH); Cancer Prevention Institute of California, Freemont, CA (AWH); Division of Epidemiology, Department of Health Research and Policy, and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Palo Alto, CA (AWH); Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI (LNK); Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC (CI); Department of Epidemiology (KBM) and Department of Nutrition (WCW), Harvard School of Public Health, Boston, MA (KBM); Istituto di Richerche Farmacologiche, Milan, Italy (EN, DT); IMS, Inc, Rockville, MD (DP, KS); Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece (ETP); School of Public Health, Imperial C
J Natl Cancer Inst. 2014 Mar;106(3):djt465. doi: 10.1093/jnci/djt465. Epub 2014 Feb 19.
The etiology of male breast cancer is poorly understood, partly because of its relative rarity. Although genetic factors are involved, less is known regarding the role of anthropometric and hormonally related risk factors.
In the Male Breast Cancer Pooling Project, a consortium of 11 case-control and 10 cohort investigations involving 2405 case patients (n = 1190 from case-control and n = 1215 from cohort studies) and 52013 control subjects, individual participant data were harmonized and pooled. Unconditional logistic regression generated study design-specific (case-control/cohort) odds ratios (ORs) and 95% confidence intervals (CIs), with exposure estimates combined using fixed effects meta-analysis. All statistical tests were two-sided.
Risk was statistically significantly associated with weight (highest/lowest tertile: OR = 1.36; 95% CI = 1.18 to 1.57), height (OR = 1.18; 95% CI = 1.01 to 1.38), and body mass index (BMI; OR = 1.30; 95% CI = 1.12 to 1.51), with evidence that recent rather than distant BMI was the strongest predictor. Klinefelter syndrome (OR = 24.7; 95% CI = 8.94 to 68.4) and gynecomastia (OR = 9.78; 95% CI = 7.52 to 12.7) were also statistically significantly associated with risk, relations that were independent of BMI. Diabetes also emerged as an independent risk factor (OR = 1.19; 95% CI = 1.04 to 1.37). There were also suggestive relations with cryptorchidism (OR = 2.18; 95% CI = 0.96 to 4.94) and orchitis (OR = 1.43; 95% CI = 1.02 to 1.99). Although age at onset of puberty and histories of infertility were unrelated to risk, never having had children was statistically significantly related (OR = 1.29; 95% CI = 1.01 to 1.66). Among individuals diagnosed at older ages, a history of fractures was statistically significantly related (OR = 1.41; 95% CI = 1.07 to 1.86).
Consistent findings across case-control and cohort investigations, complemented by pooled analyses, indicated important roles for anthropometric and hormonal risk factors in the etiology of male breast cancer. Further investigation should focus on potential roles of endogenous hormones.
男性乳腺癌的病因尚不清楚,部分原因是其相对罕见。尽管遗传因素与之相关,但人们对与人体测量和激素相关的风险因素的了解较少。
在男性乳腺癌汇集项目中,一个由 11 项病例对照和 10 项队列研究组成的联盟,共纳入 2405 例病例患者(病例对照研究 1190 例,队列研究 1215 例)和 52013 例对照,对个体参与者数据进行了协调和汇总。使用固定效应荟萃分析,结合病例对照/队列研究的条件逻辑回归生成特定的研究设计(病例对照/队列)比值比(OR)和 95%置信区间(CI)。所有统计检验均为双侧。
风险与体重(最高/最低三分位数:OR = 1.36;95%CI = 1.18 至 1.57)、身高(OR = 1.18;95%CI = 1.01 至 1.38)和体重指数(BMI;OR = 1.30;95%CI = 1.12 至 1.51)呈统计学显著相关,近期而非远期 BMI 是最强的预测因素。克莱恩费尔特综合征(OR = 24.7;95%CI = 8.94 至 68.4)和男性乳房发育症(OR = 9.78;95%CI = 7.52 至 12.7)也与风险呈统计学显著相关,这些关系与 BMI 无关。糖尿病也成为独立的危险因素(OR = 1.19;95%CI = 1.04 至 1.37)。隐睾(OR = 2.18;95%CI = 0.96 至 4.94)和睾丸炎(OR = 1.43;95%CI = 1.02 至 1.99)也存在提示性关系。虽然青春期发病年龄和不孕史与风险无关,但从未生育过的人风险显著相关(OR = 1.29;95%CI = 1.01 至 1.66)。在年龄较大时被诊断出的患者中,骨折史与风险显著相关(OR = 1.41;95%CI = 1.07 至 1.86)。
病例对照和队列研究的一致性发现,加上汇总分析,表明人体测量和激素危险因素在男性乳腺癌的发病机制中起着重要作用。进一步的研究应集中在潜在的内源性激素作用上。